07:00 , Apr 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) Mouse studies suggest inhibiting CITED2 could help treat diabetic hyperglycemia. In obese diabetic mice, small...